Artificial Intelligence (AI) in Life Sciences Market (By Offering: Software, Hardware, Services; By Deployment: On Premise, Cloud; By Application: Medical Diagnosis, Drug Discovery, Precision and Personalized Medicine, Biotechnology, Clinical Trials, Patient Monitoring) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Life Sciences Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Artificial Intelligence (AI) in Life Sciences Market, by Offering, 2023-2032
8.1.1Software
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hardware
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
9.1. Artificial Intelligence (AI) in Life Sciences Market, by Deployment, 2023-2032
9.1.1. On Premise
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cloud
9.1.2.1. Market Revenue and Forecast (2020-2032)
10.1. Artificial Intelligence (AI) in Life Sciences Market, by Application, 2023-2032
10.1.1. Medical Diagnosis
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Drug Discovery
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Precision and Personalized Medicine
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Biotechnology
10.1.4.1. Market Revenue and Forecast (2020-2032)
10.1.5. Clinical Trials
10.1.5.1. Market Revenue and Forecast (2020-2032)
10.1.6. Patient Monitoring
10.1.6.1. Market Revenue and Forecast (2020-2032)
11.1. North America
11.1.1. Market Revenue and Forecast, by Offering (2020-2032)
11.1.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.1.3. Market Revenue and Forecast, by Application (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Offering (2020-2032)
11.2.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.2.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Offering (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Offering (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Offering (2020-2032)
11.3.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.3.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Offering (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Offering (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Offering (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Application (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Offering (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.5.3. Market Revenue and Forecast, by Application (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Offering (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Application (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Offering (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Deployment (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Application (2020-2032)
12.1.IBM Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Atomwise, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Nuance Communications, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. NuMedii, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AiCure LLC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. APIXIO, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Enlitic, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sensely, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Zebra Medical Vision
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client